Antiviral Drug News and Research

RSS

Global Virus Network committed to the continued development of mRNA vaccines

The Global Virus Network (GVN), a coalition of leading human and animal virologists from 80+ Centers of Excellence and Affiliates in more than 40 countries dedicated to advancing pandemic preparedness, is unequivocally committed to the continued development and deployment of mRNA vaccines and the global scientific collaboration that makes such innovation possible.

12 Aug 2025

Hepatitis E virus also attacks organs other than the liver, study finds

A research team from Bochum and Hannover shows that the hepatitis E virus also attacks organs other than the liver.

3 Jul 2025

AI and film animation tools lead to breakthrough in coronavirus drug discovery

About 30% of all respiratory tract infections are caused by coronaviruses, leading to widespread illnesses and, in some cases, to epidemic and even pandemic outbreaks, as we experienced with the COVID-19 pandemic.

13 Jun 2025

Scientists develop promising new drug candidates against coronaviruses

A team at UC San Francisco and Gladstone Institutes has developed new drug candidates that show great promise against the virus that causes COVID-19 and potentially other coronaviruses that could cause future pandemics.

23 Apr 2025

New quinoline-based antiviral shows strong promise against SARS-CoV-2

Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

10 Apr 2025

Rutgers researchers develop promising new oral antiviral for COVID-19

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

3 Apr 2025

Current antivirals not successful in treating severe H5N1 bird flu infections

As the H5N1 avian influenza outbreak continues, scientists are working to better understand the virus's threat to human health.

17 Mar 2025

Oral antiviral drug proves successful in preventing symptomatic COVID-19 in household members

An international clinical trial has identified a medication that can help prevent symptomatic COVID-19 in people exposed within households.

12 Mar 2025

Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions.

12 Mar 2025

Updates on influenza vaccine strain recommended by WHO (2025-2026 northern hemisphere)

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, and serological analyses.

From Sino Biological Inc. 12 Mar 2025

New insights into how the Sudan virus attaches to human cells

The Sudan virus, a close relative of Ebola, has a fatality rate of 50% but remains poorly understood in terms of how it infects cells. Currently, no approved treatments exist.

4 Feb 2025

Researchers develop nanobody inhibitors to target Ebola virus

Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50%, posing a serious threat to global health and safety.

7 Jan 2025

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions.

11 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024

Researchers expose practices of crisis pregnancy centers across the U.S.

A new study from scientists at the University of California San Diego introduces a powerful new approach to understanding the operation of crisis pregnancy centers, non-profit organizations dedicated to an anti-abortion agenda.

2 Dec 2024

Leritrelvir shows high efficacy against SARS-CoV-2 protease mutations

Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the original wild-type strains to the highly transmissible Omicron variant.

6 Nov 2024

Long-term low-dose antiviral treatment reduces eye disease risk from shingles

Long-term, low-dose antiviral treatment reduces the risk for potentially vision-damaging bouts of inflammation and infection, as well as pain, which occur when shingles affects the eye, according to new research presented October 19 at the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago.

20 Oct 2024

New study links persistent SARS-CoV-2 proteins to long COVID symptoms

Brigham researchers found people with wide-ranging long COVID symptoms were twice as likely to have SARS-CoV-2 proteins in their blood, compared to those without long COVID symptoms.

9 Oct 2024

Antiviral drug molnupiravir linked to new mutations in SARS-CoV-2

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown.

26 Sep 2024

Drug-resistant SARS-CoV-2 variants found in immunocompromised patients

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population found researchers at Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University and the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

18 Sep 2024